[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"exercise-physiology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:exercise-physiology":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,58,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100610361","using-a-personalized-decision-support-tool-to-help-people-with-type-1-diabetes-manage-exercise-100610361",false,"NCT07226583","Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage Exercise","Net-IOB & Exercise Toolkit Pilot Trial: Randomized, Crossover Evaluation of a Behavioral Decision Support Advisor to Improve Glycemic Safety During and After Exercise in Adults With Type 1 Diabetes (NEXT)","NEXT","Inclusion Criteria Inclusion Criteria: All Participants (Type 1 Diabetes and Healthy Control Groups)\n\n* Adults between the age of 18-60 years\n* Able to perform moderate intensity walking for 60 minutes (target 40-60% age-predicted maximal heart rate).\n* Willing and able to comply with study procedures, including supervised exercise visits and device wear\n* Able to provide written informed consent\n\nInclusion Criteria: Type 1 Diabetes Group Only\n\n* Clinical diagnosis of type 1 diabetes for \\>1 year, based on the investigator's clinical judgement\n* Current use of continuous subcutaneous insulin infusion with Tandem Control-IQ and a compatible continuous glucose monitor (CGM) for \\>1 month prior to enrollment\n* Stable insulin delivery regimen, with no planned changes to insulin pump settings or insulin dosing strategy during the study period\n* Consistent CGM use during the month prior to enrollment (\\>80% data availability)\n\nInclusion Criteria: Health Control Group Only\n\n* No diagnosis of diabetes or other disorders of glucose metabolism\n* Not using insulin or glucose-lowering medications\n\nExclusion Criteria Exclusion Criteria: All Participants\n\n* Intercurrent illness or medical condition that precludes safe participation in moderate-intensity exercise (e.g., unstable cardiopulmonary disease, uncontrolled arrhythmia, or uncontrolled hypertension), as previously assessed by the participant's primary care physician\n* Known coronary artery disease with symptoms limiting moderate physical activity, or history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the past 12 months\n* Pregnancy, lactation, or plans to become pregnant during the study period\n* Renal insufficiency with estimated GFR \\\u003C45 mL\u002Fmin\u002F1.73 m², dialysis dependence, or adrenal insufficiency\n* Concurrent participation in another interventional drug or device study within 30 days prior to enrollment\n* Inability to comply with study procedures or safety requirements (e.g., inability to achieve target heart-rate zone, attend scheduled visits, or enable required device data access), or otherwise deemed unsuitable by the investigator\n\nExclusion Criteria: Type 1 Diabetes Group Only\n\n* Use of non-CSII insulin delivery, including long-acting injectable or inhaled insulin, during the study period\n* Use of medications with potential to substantially affect glycemia (e.g., SGLT-2 inhibitors, GLP-1 receptor agonists, or GIP agonists), unless on a stable regimen with no planned changes during the study\n* Use of systemic corticosteroids within 4 weeks prior to participation\n* History of severe hypoglycemia (requiring third-party assistance) or diabetic ketoacidosis within the prior 6 months",true,"ALL","18 Years","60 Years",{"count":22,"type":23},20,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study evaluates a clinician-facing decision-support toolkit designed to assist adults with type 1 diabetes in preparing for moderate-intensity exercise. The netIOB \\& Exercise Toolkit (NEXT) integrates recent glucose data and insulin delivery history to provide individualized suggestions regarding exercise timing, insulin adjustments, and carbohydrate intake.\n\nAdults with type 1 diabetes will complete three supervised exercise sessions under different pre-exercise guidance approaches:\n\n(A) published consensus-based standard-of-care guidance, (B) usual personal care routines, and (C) guidance informed by the NEXT Toolkit.\n\nA healthy adult control group will complete a single supervised exercise session to provide comparative physiologic data.",[29,30,31,32],"Type 1 Diabetes Mellitis","Type 1 Diabetes (T1D)","Type 1 Diabetes Mellitus (T1DM)","Exercise Physiology",[34,35,36,37,38,39,40,41,42,43,44],"Type 1 Diabetes","T1D","T1DM","Continuous Glucose Monitoring","Insulin Dosing","CGM","Insulin Pump","Exercise","carbohydrate Intake","closed-loop system","hybrid closed-loop","NOT_YET_RECRUITING","2026-05-11",{"date":48,"type":49},"2026-05-14","ACTUAL",{"date":51,"type":23},"2026-04",{"date":53,"type":23},"2026-08",{"name":55,"class":56},"Stanford University","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":75,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":57},"100623223","molecular-indicators-of-systematic-fitness-100623223","NCT07393841","Molecular Indicators of Systematic Fitness","MISFIT","Inclusion Criteria:\n\n* Be ≥18 years old\n* Be able to understand and provide informed consent (English; additional languages may be added via amendment with translated materials)\n* Be willing to complete VO₂max testing, blood draw, and questionnaires.\n* Be able to safely perform maximal\u002Fsymptom-limited exercise testing as determined by: PAR-Q+ screening and investigator review (included as an attachment) and resting vitals screening (heart rate)\n\nExclusion Criteria:\n\n* Conditions that, in the investigator's judgment, or a medical doctor, makes maximal exercise testing unsafe (e.g., unstable cardiovascular symptoms)\n* Contraindications or unwillingness to undergo venipuncture\n* Acute illness (fever, significant respiratory illness) at the time of testing\n* Failure to comply with procedures.",{"count":66,"type":23},250,"OBSERVATIONAL","The goal of this study is to characterize associations between cardiorespiratory fitness, as measured by VO₂max\u002FVO₂peak, and blood-based molecular measurements in adults. This is an observational study where research staff measures VO₂max\u002FVO₂peak and collects fasted, resting blood samples on the same day. The main questions it aims to answer are:\n\n1. Can a multi-analyte blood panel accurately predict directly measured VO₂max\u002FVO₂peak?\n2. How do these blood-based features vary across age, sex, and self-reported or documented physical activity profiles?\n3. Are the predictor analytes able to capture changes in VO₂max\u002FVO₂peak caused by a self-directed intervention (e.g., training for a marathon)?\n4. What is the analytic reliability of the predictor biomarkers?",[70,71,72,73,32,74],"Healthy Adult","Fitness Testing","Athlete","Aging","Human Performance",[76,77,78,79,80,81,82,83,84],"VO2peak","VO2max","cardiorespiratory fitness","proteomics","blood biomarkers","cardiovascular health","oxygen transport","exercise performance","functional capacity","RECRUITING","2026-02-02",{"date":88,"type":49},"2026-02-06",{"date":90,"type":49},"2026-01-05",{"date":92,"type":23},"2028-05-10",{"name":94,"class":95},"VO Health, Inc.","INDUSTRY",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":17,"sex":18,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":24,"phases":107,"briefSummary":108,"conditions":109,"keywords":113,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":57},"100610621","exercise-intensity-and-postprandial-effects-of-breaking-sedentary-behavior-in-overweight-adults-100610621","NCT07229963","Exercise Intensity and Postprandial Effects of Breaking Sedentary Behavior in Overweight Adults","Postprandial Cardiometabolic Effects of Interrupting Sedentary Behavior With Exercise of Varying Intensity in Healthy Overweight Adults","Inclusion Criteria\n\n* Being physically inactive (not doing at least 150 minutes\u002Fweek of structured exercise).\n* Having a physical activity level of \\\u003C5000 steps\u002Fday.\n* Having a BMI between 25 and 29.9 kg\u002Fm2.\n* Having a history of regular menstrual cycles for female participants.\n* Having medical examination approval.\n\nExclusion Criteria\n\n* Taking any acute or chronic medication or supplement that may affect metabolism.\n* Having an acute or chronic illness that limits exercise (musculoskeletal problems, cardiovascular disorders, respiratory problems, etc.).\n* Consuming tobacco products.\n* Meeting 3 or more of the metabolic syndrome criteria (waist circumference of 102 cm or more in men, 88 cm or more in women, triglyceride level of 150 mg\u002FdL or higher, HDL cholesterol level below 40 mg\u002FdL in men and 50 mg\u002FdL in women, blood pressure of 130\u002F85 mmHg or higher, fasting blood glucose level of 100 mg\u002FdL (5.6 mg\u002FL) or higher).","35 Years","45 Years",{"count":106,"type":23},16,[26],"The purpose of this study is twofold: (1) to determine whether breaking up prolonged sitting with aerobic or sprint cycling breaks reduces postprandial blood glucose, insulin, CRP, and blood pressure, which are established risk markers for cardiometabolic diseases; and (2) to assess substrate oxidation during this period in order to identify which exercise condition promotes the greatest increase in fat oxidation.",[110,111,112,32],"Cardiovascular Risk Markers","Substrate Oxidation","Postprandial Metabolism",[41,114,115,116,117],"Sedentary behavior","Cardiometabolic health","Postprandial metabolism","overweight","2025-11-13",{"date":120,"type":49},"2025-11-17",{"date":122,"type":23},"2025-11-25",{"date":124,"type":23},"2026-06-15",{"name":126,"class":56},"Hacettepe University"]